ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GYRE Gyre Therapeutics Inc

12.61
-0.93 (-6.87%)
After Hours
Last Updated: 18:46:37
Delayed by 15 minutes

Period:

Draw Mode:

Volume 35,751
Bid Price 11.99
Ask Price 12.61
News -
Day High 13.81

Low
5.88

52 Week Range

High
30.40

Day Low 12.61
Company Name Stock Ticker Symbol Market Type
Gyre Therapeutics Inc GYRE NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.93 -6.87% 12.61 18:46:37
Open Price Low Price High Price Close Price Prev Close
13.67 12.61 13.81 12.61 13.54
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,260 35,751 $ 13.12 $ 469,070 - 5.88 - 30.40
Last Trade Time Type Quantity Stock Price Currency
19:30:57 5 $ 12.27 USD

Gyre Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
31.93M 2.53M - 113.45M -92.93M -36.71 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Gyre Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No GYRE Message Board. Create One! See More Posts on GYRE Message Board See More Message Board Posts

Historical GYRE Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week15.4515.9112.6114.0347,123-2.84-18.38%
1 Month15.5817.2512.6115.2762,866-2.97-19.06%
3 Months21.8122.904912.6116.4361,194-9.20-42.18%
6 Months17.2130.4010.4119.1392,961-4.60-26.73%
1 Year7.0030.405.8818.4291,0395.6180.14%
3 Years7.0030.405.8818.4291,0395.6180.14%
5 Years7.0030.405.8818.4291,0395.6180.14%

Gyre Therapeutics Description

Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in the clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.